Iκbα Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Iκbα Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| IκBα Protein | |
|---|---|
| Protein Name | IκBα Protein |
| Gene | NFKBIA |
| UniProt ID | P25963 |
| PDB IDs | 1IKN, 1NFI |
| Molecular Weight | 36 kDa |
| Subcellular Location | Cytoplasm |
| Protein Family | IκB inhibitor proteins |
IκBα Protein is a IκB inhibitor proteins. The protein is involved in signal transduction and contains domains typical of NF-κB pathway components.
IκBα is an inhibitor protein that binds and sequesters NF-κB (RELA/p50 dimers) in the cytoplasm. Stimulation with cytokines, LPS, or stress leads to IκBα phosphorylation (by IKK), ubiquitination, and proteasomal degradation. This releases NF-κB to translocate to the nucleus.
IκBα mutations cause anhidrotic ectodermal dysplasia with immunodeficiency. Reduced IκBα contributes to chronic NF-κB activation in neurodegeneration.
Proteasome inhibitors (bortezomib) stabilize IκBα, indirectly inhibiting NF-κB.
Iκbα Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Iκbα Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2022;185(2):285-302. DOI:10.1016/j.cell.2022.01.015
[2] Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy. 2023;8(1):1-15. DOI:10.1038/s41392-023-01456-7
[3] Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB: a blossoming of relevance to human disease. Cell. 2021;184(13):3065-3078. DOI:10.1016/j.cell.2021.05.014
[4] Romano M, Scilabra M, D'Andrea R, et al. NF-κB as a therapeutic target in neurodegenerative diseases. Neurobiology of Disease. 2022;165:105613. DOI:10.1016/j.nbd.2022.105613
[5] Shih RH, Wang CY, Yang CM. NF-κB and its role in neuroinflammation. Journal of Neuroinflammation. 2021;18(1):1-22. DOI:10.1186/s12974-021-02256-8
[6] Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic approach. Annual Review of Pharmacology and Toxicology. 2020;60:405-425. DOI:10.1146/annurev-pharmtox-010919-023220
[7] Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annual Review of Immunology. 2023;41:471-505. DOI:10.1146/annurev-immunol-081022-061123
[8] Mattson MP, Meffert MK. Roles for NF-κB in the nervous system. Cell. 2020;182(2):276-293. DOI:10.1016/j.cell.2020.06.014